Live Breaking News & Updates on Clinical Program Expected To

Stay updated with breaking news from Clinical program expected to. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results

First-Quarter 2023 Results:
Net Sales of $832.1 Million
GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million
TEPEZZA® Net Sales of $405.3 Million
. | May 3, 2023 ....

United States , Tim Walbert , Viela Bio Inc , Companies To Work , Top Biotechnology Pharmaceutical Company , Clinical Program Expected To , Amgen Inc , Apotex Inc , United States Federal Trade Commission , Net Sales , Recent Company Highlights , Positive Topline Data , Low Clinical Activity Score , Thyroid Eye Disease , Specify Treatment , Disease Activity , Second Population , Syndrome Phase , Only Phase , Syndrome Trial , Primary Endpoint , Both Patient Populations , Program Expected , Two Daxdilimab Phase , Discoid Lupus Erythematosus , Expect Amgen Transaction ,

Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Fourth-Quarter 2022 Results: Net Sales of $942.0 Million GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses ....

United States , Dennis Riedl , Geoff Curtis , Tim Walbert , Tina Ventura , Ray Gordon , Erin Linnihan , Clinical Program Expected To , Alkem Laboratories Inc , Amgen Inc , Corporate Affairs , Apotex Inc , Net Sales , Year Over Increase , Record Adjusted , Operating Cash Flow , Recent Company Highlights , Transaction Expected , Positive Topline Data , Second Population , Syndrome Phase , Only Phase , Syndrome Trial , Primary Endpoint , Both Patient Populations , Program Expected ,